MM
MCID: MLT019
MIFTS: 83

Multiple Myeloma (MM) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Blood diseases, Immune diseases

Aliases & Classifications for Multiple Myeloma

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 35LifeMap Discovery®, 37MedGen, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Multiple Myeloma:

Name: Multiple Myeloma 52 35 11 48 24 25 54 70 12 38 39 13 68
Plasma Cell Myeloma 11 48 54 50
Medullary Plasmacytoma 25 54 68
Plasma Cell Dyscrasia 48 25 68
Myelomatosis 48 25 54
Primary Systemic Amyloidosis 54 68
Primary Amyloidosis 54 68
Myeloma - Multiple 48 27
Kahler's Disease 25 54
Kahler Disease 48 25
 
Myeloma, Multiple Amyloidosis, Systemic, Included 52
Immunoglobulin Deposition Disease 68
Systemic Al Amyloidosis 54
Light-Chain Amyloidosis 54
Kahler-Bozzolo Disease 25
Plasma Cell Myelomas 25
Plasma Cell Neoplasm 68
Al Amyloidosis 54
Mm 70

Characteristics:

Orphanet epidemiological data:

54
multiple myeloma:
Prevalence: 1-9/100000 (United States),1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Europe),1-9/100000 (Australia); Age of onset: Adult
primary amyloidosis:
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult
primary systemic amyloidosis:
Inheritance: Not applicable

HPO:

64
multiple myeloma:
Inheritance: autosomal recessive inheritance, somatic mutation

Classifications:



External Ids:

OMIM52 254500
Disease Ontology11 DOID:9538
ICD1030 C90.0, C90.00
ICD9CM32 203.0
MeSH39 D009101
NCIt45 C3242
ICD10 via Orphanet31 E85.0, E85.1, E85.2 E85.3, C90.0, E85.9, more
MESH via Orphanet40 D009101, C531616
UMLS via Orphanet69 C0026764, C0268381

Summaries for Multiple Myeloma

About this section
NIH Rare Diseases:48 Multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. when present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs. the exact underlying cause of multiple myeloma is currently unknown. factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, african american race, radiation exposure, a family history of the condition, obesity, and/or a personal history of monoclonal gammopathy of undetermined significance (mgus). treatment varies based on many factors, but may include one or more of the following interventions: chemotherapy, corticosteroid medications, targeted therapy, stem cell transplant, biological therapy, radiation therapy, surgery and/or watchful waiting. last updated: 3/12/2016

MalaCards based summary: Multiple Myeloma, also known as plasma cell myeloma, is related to igh-related multiple myeloma and plasmacytoma, and has symptoms including Array, Array and Array. An important gene associated with Multiple Myeloma is LIG4 (DNA Ligase 4), and among its related pathways are Hepatitis C and Hepatocellular Carcinoma and Cytokine production by Th17 cells in CF (Mouse model). The drugs interferon alfa-2b and procarbazine have been mentioned in the context of this disorder. Affiliated tissues include the plasma cells in bone marrow, bone and bone marrow, and related mouse phenotypes are digestive/alimentary and liver/biliary system.

Disease Ontology:11 A myeloid neoplasm that is located in the plasma cells in bone marrow.

Genetics Home Reference:25 Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting.

OMIM:52 Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells... (254500) more...

MedlinePlus:38 Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. these cells are part of your immune system, which helps protect the body from germs and other harmful substances. in time, myeloma cells collect in the bone marrow and in the solid parts of bones. no one knows the exact causes of multiple myeloma, but it is more common in older people and african americans. it can run in families. common symptoms may include bone pain, often in the back or ribs broken bones weakness or fatigue weight loss frequent infections and fevers feeling very thirsty frequent urination doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. your treatment depends on how advanced the disease is and whether you have symptoms. if you have no symptoms, you may not need treatment right away. if you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

UniProtKB/Swiss-Prot:70 Multiple myeloma: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

Wikipedia:71 Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood... more...

Related Diseases for Multiple Myeloma

About this section

Diseases in the Multiple Myeloma family:

Igh-Related Multiple Myeloma

Diseases related to Multiple Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 409)
idRelated DiseaseScoreTop Affiliating Genes
1igh-related multiple myeloma11.9
2plasmacytoma11.6
3plasma cell leukemia11.6
4light chain deposition disease11.5
5monoclonal gammopathy of uncertain significance11.5
6hematopoietic stem cell transplantation11.2
7plasma cell neoplasm11.2
8cryoglobulinemia11.2
9epidermolysis bullosa acquisita11.2
10smoldering myeloma11.2
11hypoaldosteronism11.2
12indolent myeloma10.9
13microphthalmia, isolated 610.9
14miyoshi muscular dystrophy 110.8
15medial medullary syndrome10.8
16extramedullary plasmacytoma10.7
17leukemia10.4
18lymphoma10.4
19polycystic bone disease10.3CCND1, FGFR3, IRF4, NCAM1
20keratoconus10.3DKK1, IL6, IL6R
21theileriasis10.3CCND1, IL6, IL6R, NCAM1
22amyloidosis10.3
23endotheliitis10.2
24ethmoid sinus schneiderian papilloma10.2CD19, FGFR3, IL6, NCAM1
25verrucous carcinoma10.2CD19, MCL1, NCAM1
26childhood pleomorphic rhabdomyosarcoma10.2CD19, IL6, NCAM1
27gingival recession10.2CCND1, IRF4, MCL1
28pulmonary fibrosis, idiopathic10.1CCND1, CCND3, CD19, IRF4, MCL1
29neuropathy10.1
30ectodermal dysplasia10.1CCND1, CDK4, IRF4
31macroglobulinemia10.1
32al amyloidosis10.1
33extraocular retinoblastoma10.1CCND1, CCND3, CDK4
34chronic lymphocytic leukemia10.0
35integumentary system benign neoplasm10.0CCND1, CCND3, CDK4
36glomerulonephritis10.0
37post-surgical hypoinsulinemia10.0CCND1, CCND3, CDK4
38purpura10.0
39cutis laxa10.0
40hodgkin lymphoma10.0
41melanoma metastasis10.0CCND1, CCND3, CD19, CDK4, MCL1
42acquired cutis laxa9.9
43acute leukemia9.9
44hepatitis9.9
45osteonecrosis9.9
46fanconi syndrome9.9
47osteonecrosis of the jaw9.9
48myelodysplastic syndrome9.9
49hypoxia9.9
50arthritis9.9

Graphical network of the top 20 diseases related to Multiple Myeloma:



Diseases related to multiple myeloma

Symptoms & Phenotypes for Multiple Myeloma

About this section

Symptoms by clinical synopsis from OMIM:

254500

Clinical features from OMIM:

254500

Human phenotypes related to Multiple Myeloma:

 54 64 (show all 80)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteopenia64 54 Very frequent (99-80%) HP:0000938
2 pathologic fracture64 54 Very frequent (99-80%) HP:0002756
3 nephrotic syndrome64 54 Frequent (79-30%) HP:0000100
4 nephropathy64 54 Frequent (79-30%) HP:0000112
5 anemia64 54 Frequent (79-30%) HP:0001903
6 acute kidney injury64 54 Frequent (79-30%) HP:0001919
7 hyperproteinemia64 54 Frequent (79-30%) HP:0002152
8 bone pain64 54 Frequent (79-30%) HP:0002653
9 increased igg level64 54 Frequent (79-30%) HP:0003237
10 elevated serum creatinine64 54 Frequent (79-30%) HP:0003259
11 generalized muscle weakness64 54 Frequent (79-30%) HP:0003324
12 decreased antibody level in blood64 54 Frequent (79-30%) HP:0004313
13 fatigue64 54 Frequent (79-30%) HP:0012378
14 abnormality of the bladder64 54 Occasional (29-5%) HP:0000014
15 tall stature64 54 Occasional (29-5%) HP:0000098
16 weight loss64 54 Occasional (29-5%) HP:0001824
17 spinal cord compression64 54 Occasional (29-5%) HP:0002176
18 vertebral compression fractures64 54 Occasional (29-5%) HP:0002953
19 hypercalcemia64 54 Occasional (29-5%) HP:0003072
20 increased iga level64 54 Occasional (29-5%) HP:0003261
21 paresthesia64 54 Occasional (29-5%) HP:0003401
22 abnormality of vitamin b12 metabolism64 54 Occasional (29-5%) HP:0004341
23 functional abnormality of the gastrointestinal tract64 54 Occasional (29-5%) HP:0012719
24 splenomegaly64 54 Very rare (<4-1%) HP:0001744
25 pleural effusion64 54 Very rare (<4-1%) HP:0002202
26 lymphadenopathy64 54 Very rare (<4-1%) HP:0002716
27 renal insufficiency54 Frequent (79-30%)
28 proteinuria54 Frequent (79-30%)
29 enlarged kidneys54 Frequent (79-30%)
30 macroglossia54 Occasional (29-5%)
31 xerostomia54 Occasional (29-5%)
32 hematuria54 Occasional (29-5%)
33 goiter54 Occasional (29-5%)
34 adrenal insufficiency54 Occasional (29-5%)
35 purpura54 Occasional (29-5%)
36 keratoconjunctivitis sicca54 Occasional (29-5%)
37 polyneuropathy54 Occasional (29-5%)
38 hepatomegaly54 Frequent (79-30%)
39 congestive heart failure54 Frequent (79-30%)
40 hypertrophic cardiomyopathy54 Very frequent (99-80%)
41 bradycardia54 Occasional (29-5%)
42 asplenia54 Occasional (29-5%)
43 constipation54 Frequent (79-30%)
44 malabsorption54 Occasional (29-5%)
45 dyspnea54 Frequent (79-30%)
46 gastrointestinal hemorrhage54 Occasional (29-5%)
47 autonomic dysregulation54 Occasional (29-5%)
48 gastrointestinal dysmotility54 Occasional (29-5%)
49 osteoarthritis54 Occasional (29-5%)
50 upper airway obstruction54 Occasional (29-5%)
51 arthralgia54 Frequent (79-30%)
52 increased antibody level in blood54 Very frequent (99-80%)
53 elevated alkaline phosphatase54 Frequent (79-30%)
54 abnormality of chromosome segregation54 Frequent (79-30%)
55 arthropathy54 Frequent (79-30%)
56 abnormal ekg54 Frequent (79-30%)
57 skeletal muscle hypertrophy54 Occasional (29-5%)
58 arrhythmia54 Frequent (79-30%)
59 intermittent claudication54 Occasional (29-5%)
60 orthostatic hypotension due to autonomic dysfunction54 Occasional (29-5%)
61 hypertension54 Occasional (29-5%)
62 aortic root dilatation54 Occasional (29-5%)
63 autonomic bladder dysfunction54 Occasional (29-5%)
64 waldenstrom macroglobulinemia54 Frequent (79-30%)
65 abnormality of bone marrow cell morphology54 Occasional (29-5%)
66 interstitial pulmonary disease54 Frequent (79-30%)
67 multiple myeloma64 54 Frequent (79-30%) HP:0006775
68 abnormal blistering of the skin54 Occasional (29-5%)
69 abnormality of the submandibular glands54 Occasional (29-5%)
70 mechanical ileus54 Occasional (29-5%)
71 edema of the lower limbs54 Frequent (79-30%)
72 plasmacytoma54 Occasional (29-5%)
73 acute infectious pneumonia54 Frequent (79-30%)
74 hepatitis54 Occasional (29-5%)
75 chronic constipation54 Frequent (79-30%)
76 jaw claudication54 Occasional (29-5%)
77 pulmonary edema54 Frequent (79-30%)
78 papule54 Occasional (29-5%)
79 skin nodule54 Occasional (29-5%)
80 amyloidosis64 HP:0011034

MGI Mouse Phenotypes related to Multiple Myeloma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538110.9CCND1, CD19, CDK4, FGFR3, IL6, LIG4
2MP:000537010.8CCND3, CD19, CDK4, CRBN, IL6, IL6R
3MP:000537910.8CCND1, CCND3, CDK4, CRBN, IL6, IL6R
4MP:000539710.7CCND1, CCND3, CD19, CDK4, FGFR3, IL6
5MP:000538710.7CCND1, CCND3, CD19, CDK4, FGFR3, IL6
6MP:000200610.7CCND1, CCND3, CD19, CDK4, FGFR3, IL6
7MP:000538610.7CCND1, CCND3, CD19, CDK4, CRBN, FGFR3
8MP:000537810.6CCND1, CCND3, CD19, CDK4, CRBN, DKK1
9MP:001076810.4CCND1, CCND3, CD19, CDK4, DKK1, FGFR3
10MP:000287310.0CCND1, CCND3, CD19, CDK4, DAZAP2, FGFR3

Drugs & Therapeutics for Multiple Myeloma

About this section

FDA approved drugs:

(show all 17)
id Drug Name Active Ingredient(s)16 Company Approval Date
1
Aredia16 44 PAMIDRONATE DISODIUM Chiron August 1996
FDA Label: Aredia
Disease/s that Drug Treats:osteolytic bone metastases of breast cancer
Indications and Usage:16 Hypercalcemia of MalignancyAredia, in conjunction with adequate hydration, is indicated for the treatment of moderate or severehypercalcemia associated with malignancy, with or without bone metastases. Patients who have eitherepidermoid or non-epidermoid tumors respond to treatment with Aredia. Vigorous saline hydration, anintegral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made torestore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia maybe treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patientsshould be hydrated adequately throughout the treatment, but overhydration, especially in those patientswho have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction ofhypovolemia. The safety and efficacy of Aredia in the treatment of hypercalcemia associated withhyperparathyroidism or with other non-tumor-related conditions has not been established.Paget’s DiseaseAredia is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. Theeffectiveness of Aredia was demonstrated primarily in patients with serum alkaline phosphatase ≥3 timesthe upper limit of normal. Aredia therapy in patients with Paget’s disease has been effective in reducingserum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by≥30% in at least 80% of patients. Aredia therapy has also been effective in reducing these biochemicalmarkers in patients with Paget’s disease who failed to respond, or no longer responded to othertreatments.Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of MultipleMyelomaAredia is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolyticbone metastases of breast cancer and osteolytic lesions of multiple myeloma. The Aredia treatment effectappeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the studyof those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated(see CLINICAL PHARMACOLOGY, Osteolytic Bone Metastases of Breast Cancer and OsteolyticLesions of Multiple Myeloma, Clinical Trials section).
DrugBank Targets:14 1. Farnesyl pyrophosphate synthase;2. Hydroxylapatite
Mechanism of Action:16 
Target: bone resorption; FPP synthase
Action: inhibitor
FDA: The principal pharmacologic action of Aredia is inhibition of bone resorption. Although the mechanism ofantiresorptive action is not completely understood, several factors are thought to contribute to this action.Aredia adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolutionof this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activitycontributes to inhibition of bone resorption. In animal studies, at doses recommended for the treatment ofhypercalcemia, Aredia inhibits bone resorption apparently without inhibiting bone formation andmineralization. Of relevance to the treatment of hypercalcemia of malignancy is the finding that Arediainhibits the accelerated bone resorption that results from osteoclast hyperactivity induced by varioustumors in animal studies.
2
Busulfex16 44 BUSULFAN Orphan Medical February 1999
FDA Label: Busulfex
Disease/s that Drug Treats:leukemia
Indications and Usage:16 BUSULFEX is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimenprior to allogeneic hematopoietic progenitor cell transplantation forchronic myelogenous leukemia (CML) (1)
DrugBank Targets:14 DNA
Mechanism of Action:16 
Target: DNA
Action: alkylyzer
FDA: Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of afour-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This producesreactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity ofbusulfan.
3
Doxil16 44 DOXORUBICIN HYDROCHLORIDE Alza June 1999
FDA Label: Doxil
Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies
Indications and Usage:16 DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy.
DrugBank Targets:14 1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:16 
Target: nucleic acidsynthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
4
Evista16 44 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
FDA Label: Evista
Disease/s that Drug Treats:osteoporosis and reduction of breast cancer risk in postmenopausal women
Indications and Usage:16 EVISTA is an estrogen agonist/antagonist indicated for Treatment and prevention of osteoporosis in postmenopausal women.(1.1)
DrugBank Targets:14 1. Estrogen receptor;2. Estrogen receptor beta
Mechanism of Action:16 
Target: estrogenic pathways
Action: can be an activator or antooagonist
FDA: Decreases in estrogen levels after oophorectomy or menopause lead to increases in bone resorption andaccelerated bone loss. Bone is initially lost rapidly because the compensatory increase in bone formation isinadequate to offset resorptive losses. In addition to loss of estrogen, this imbalance between resorption andformation may be due to age-related impairment of osteoblasts or their precursors. In some women, these changeswill eventually lead to decreased bone mass, osteoporosis, and increased risk for fractures, particularly of the spine,hip, and wrist. Vertebral fractures are the most common type of osteoporotic fracture in postmenopausal women.The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This bindingresults in activation of certain estrogenic pathways and blockade of others. Thus, raloxifene is an estrogenagonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM).Raloxifene decreases resorption of bone and reduces biochemical markers of bone turnover to thepremenopausal range. These effects on bone are manifested as reductions in the serum and urine levels of boneturnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in bone mineraldensity (BMD), and decreases in incidence of fractures.
5
Farydak16 44 PANOBINOSTAT LACTATE Novartis February 2015
FDA Label: Farydak
Disease/s that Drug Treats:Multiple myeloma
Indications and Usage:16 FARYDAK, a histone deacetylase inhibitor, in combination with bortezomiband dexamethasone, is indicated for the treatment of patients with multiplemyeloma who have received at least 2 prior regimens, including bortezomiband an immunomodulatory agent. This indication is approved underaccelerated approval based on progression free survival. Continued approvalfor this indication may be contingent upon verification and description ofclinical benefit in confirmatory trials. (1)
DrugBank Targets: -
Mechanism of Action:16 
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: FARYDAK is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs atnanomolar concentrations. HDACs catalyze the removal of acetyl groups from the lysine residues of histonesand some non-histone proteins. Inhibition of HDAC activity results in increased acetylation of histone proteins,an epigenetic alteration that results in a relaxing of chromatin, leading to transcriptional activation. In vitro,Reference ID: 3699607 panobinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/orapoptosis of some transformed cells. Increased levels of acetylated histones were observed in xenografts frommice that were treated with panobinostat. Panobinostat shows more cytotoxicity towards tumor cells comparedto normal cells.
6
Kyprolis16 44 CARFILZOMIB Onyx Pharmaceuticals July 2012
FDA Label: Kyprolis
Disease/s that Drug Treats:multiple myeloma
Indications and Usage:16 Kyprolis is a proteasome inhibitor that is indicated in combination with lenalidomide and dexamethasone for the treatment ofpatients with relapsed multiple myeloma who have received one to threeprior lines of therapy . (1, 14) as a single agent for the treatment of patients with multiple myeloma whohave received at least two prior therapies including bortezomib and animmunomodulatory agent and have demonstrated disease progression on orwithin 60 days of completion of the last therapy. Approval is based onresponse rate. Clinical benefit, such as improvement in survival orsymptoms, has not been verified. (1, 14)
DrugBank Targets:14 1. Proteasome subunit beta type-5;2. Proteasome subunit beta type-8;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-9;5. Proteasome subunit beta type-2;6. Proteasome subunit beta type-10
Mechanism of Action:16 
Target: tetrapeptide epoxyketone proteasome
Action: inhibitor
FDA: Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to theN-terminal threonine-containing active sites of the 20S proteasome, the proteolytic coreparticle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptoticactivities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibitedproteasome activity in blood and tissue and delayed tumor growth in models of multiplemyeloma, hematologic, and solid tumors.
7
Mozobil16 44 PLERIXAFOR Genzyme December 2008
FDA Label: Mozobil
Disease/s that Drug Treats:non-Hodgkin’s lymphoma and multiple myeloma
Indications and Usage:16 Mozobil, a hematopoietic stem cell mobilizer, is indicated in combinationwith granulocyte-colony stimulating factor (G-CSF) to mobilizehematopoietic stem cells (HSCs) to the peripheral blood for collection andsubsequent autologous transplantation in patients with non-Hodgkin’slymphoma and multiple myeloma. (1)
DrugBank Targets:14 1. C-X-C chemokine receptor type 4
Mechanism of Action:16 
Target: hematopoietic stem cell/ CXCR4 chemokine receptor
Action: monilizer/ inhibitor
FDA: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognateligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play arole in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrowcompartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to themarrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules.Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoieticprogenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable ofengraftment with long-term repopulating capacity up to one year in canine transplantationmodels.
8
Pomalyst16 44 POMALIDOMIDE Celgene February 2013
FDA Label: Pomalyst
Disease/s that Drug Treats:relapsed and refractory multiple myeloma
Indications and Usage:16 POMALYST is a thalidomide analogue indicated, in combination withdexamethasone, for patients with multiple myeloma who have received atleast two prior therapies including lenalidomide and a proteasome inhibitorand have demonstrated disease progression on or within 60 days ofcompletion of the last therapy (1.1).
DrugBank Targets:14 1. Protein cereblon;2. Tumor necrosis factor;3. Prostaglandin G/H synthase 2
Mechanism of Action:16 
Target: hematopoietic tumor cells, lenalidomide-resistant multiple myeloma cell lines/ T-cells
Action: inhibitor of proliferation/ inducer of apoptosis/ enhancer of natural killer cell-mediated immunity
FDA: Pomalidomide, an analogue of thalidomide, is an immunomodulatory agent with antineoplasticactivity. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation oflenalidomide-resistant multiple myeloma cell lines and synergized with dexamethasone in bothlenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis.Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibitedproduction of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. Pomalidomidedemonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cordmodel.
9
Revlimid16 44 LENALIDOMIDE Celgene June 2013
FDA Label: Revlimid
Disease/s that Drug Treats:mantle cell lymphoma
Indications and Usage:16 REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4).
DrugBank Targets:14 1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2
Mechanism of Action:16 
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
10
Sprycel16 44 DASATINIB Bristol-Myers Squibb June 2006
FDA Label: Sprycel
Disease/s that Drug Treats:Chronic Myeloid Leukemia
Indications and Usage:16 SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+)chronic myeloid leukemia (CML) in chronic phase. (1, 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML with resistance or intolerance to prior therapy including imatinib. (1,14) adults with Philadelphia chromosome-positive acute lymphoblasticleukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14)
DrugBank Targets:14 1. Tyrosine-protein kinase ABL1;2. Proto-oncogene tyrosine-protein kinase Src;3. Ephrin type-A receptor 2;4. Tyrosine-protein kinase Lck;5. Tyrosine-protein kinase Yes;6. Mast/stem cell growth factor receptor Kit;7. Platelet-derived growth factor receptor beta;8. Signal transducer and activator of transcription 5B;9. Abelson tyrosine-protein kinase 2;10. Tyrosine-protein kinase Fyn
Mechanism of Action:16 
Target: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ kinases
Action: inhibitor
FDA: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib ispredicted to bind to multiple conformations of the ABL kinase.In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylatesensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia(CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under theconditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCRABLkinase domain mutations, activation of alternate signaling pathways involving the SRCfamily kinases (LYN, HCK), and multi-drug resistance gene overexpression.
11
Subsys16 FENTANYL Insys Therapeutics January of 2012
FDA Label: Subsys
Disease/s that Drug Treats:breakthrough cancer pain
Indications and Usage:16 SUBSYS is an opioid agonist indicated for the management of breakthroughpain in cancer patients 18 years of age and older who are already receivingand who are tolerant to opioid therapy for their underlying persistent cancerpain. Patients must remain on around-the-clock opioids when takingSUBSYS. (1)Limitations of Use:SUBSYS may be dispensed only to patients enrolled in the TIRF REMSACCESS program.
DrugBank Targets:14 1. Mu-type opioid receptor;2. Delta-type opioid receptor;3. Kappa-type opioid receptor
Mechanism of Action:16 
Target: opiod receptors?
Action: agonist
FDA: Fentanyl is an opioid agonist whose principal therapeutic action is analgesia.Other members of the class known as opioid agonists include substances such asmorphine, oxycodone, hydromorphone, codeine, and hydrocodone.
12
Velcade16 44 BORTEZOMIB Millennium Pharmaceuticals May 2003
FDA Label: Velcade
Disease/s that Drug Treats:Multiple Myeloma
Indications and Usage:16 VELCADE is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma (1.1) treatment of patients with mantle cell lymphoma (1.2)
DrugBank Targets:14 1. 26S proteasome non-ATPase regulatory subunit 2;2. 26S proteasome non-ATPase regulatory subunit 1;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-5;5. Proteasome subunit beta type-2
Mechanism of Action:16 
Target: 26S proteasome
Action: reversible inhibitor of chymotrypsin-like activity
FDA: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammaliancells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasomepathway plays an essential role in regulating the intracellular concentration of specific proteins,thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targetedproteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostaticmechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety ofcancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models,including multiple myeloma.
13
Xgeva16 44 DENOSUMAB Amgen June 2013/ November 2010
FDA Label: Xgeva
Disease/s that Drug Treats:giant cell tumor of bone/ prevention of skeletal-related events in patients with bone metastases from solid tumors
Indications and Usage:16 Xgeva is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with bone metastasesfrom solid tumors (1.1) Treatment of adults and skeletally mature adolescents with giant celltumor of bone that is unresectable or where surgical resection is likely toresult in severe morbidity (1.2, 14.2) Treatment of hypercalcemia of malignancy refractory to bisphosphonatetherapy (1.3)Limitation of use: Xgeva is not indicated for the prevention of skeletal-relatedevents in patients with multiple myeloma
DrugBank Targets:14 1. Tumor necrosis factor ligand superfamily member 11
Mechanism of Action:16 
Target: RANKL
Action: modulator of calcium release
FDA: Xgeva binds to RANKL, a transmembrane or soluble protein essential for the formation, function, andsurvival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release frombone. Increased osteoclast activity, stimulated by RANKL, is a mediator of bone pathology in solidtumors with osseous metastases. Similarly, giant cell tumors of bone consist of stromal cells expressingRANKL and osteoclast-like giant cells expressing RANK receptor, and signaling through the RANKreceptor contributes to osteolysis and tumor growth. Xgeva prevents RANKL from activating itsreceptor, RANK, on the surface of osteoclasts, their precursors, and osteoclast-like giant cells.
14
Zoladex16 44 GOSERELIN ACETATE AstraZeneca January 1996
FDA Label: Zoladex
Disease/s that Drug Treats:prostate cancer
Indications and Usage:16 ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicatedfor: Use in combination with flutamide for the management of locally confinedcarcinoma of the prostate (1.1) Palliative treatment of advanced carcinoma of the prostate (1.2) The management of endometriosis (1.3) Use as an endometrial-thinning agent prior to endometrial ablation fordysfunctional uterine bleeding (1.4) Use in the palliative treatment of advanced breast cancer in pre- andperimenopausal women (1.5)
DrugBank Targets:14 1. Lutropin-choriogonadotropic hormone receptor;2. Gonadotropin-releasing hormone receptor
Mechanism of Action:16 
Target: pituitary gonadotropinsecretion
Action: inhibitor
FDA: ZOLADEX is a synthetic decapeptide analogue of GnRH. ZOLADEX acts as an inhibitor of pituitary gonadotropinsecretion when administered in the biodegradable formulation. In animal and in vitro studies, administration of goserelinresulted in the regression or inhibition of growth of the hormonally sensitive dimethylbenzanthracene (DMBA)-inducedrat mammary tumor and Dunning R3327 prostate tumor.
15
Zometa16 44 ZOLEDRONIC ACID Novartis August 2001/ February 2002
FDA Label: Zometa
Disease/s that Drug Treats:Hypercalcemia of malignancy/ Multiple myeloma; bone metastases from solid tumors
Indications and Usage:16 Zometa is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bonemetastases from solid tumors, in conjunction with standard antineoplastictherapy. Prostate cancer should have progressed after treatment with atleast one hormonal therapy. (1.2)Important limitation of use: The safety and efficacy of Zometa has not beenestablished for use in hyperparathyroidism or nontumor-relatedhypercalcemia. (1.3)
DrugBank Targets:14 1. Farnesyl pyrophosphate synthase;2. Geranylgeranyl pyrophosphate synthase;3. Hydroxylapatite
Mechanism of Action:16 
Target: bone resorption
Action: inhibitor
FDA: The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although theantiresorptive mechanism is not completely understood, several factors are thought to contribute to this action.In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid alsoblocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acidinhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factorsreleased by tumors.
16
Adempas16 RIOCIGUAT Bayer Healthcare Pharmaceuticals October 2013
FDA Label: Adempas
Disease/s that Drug Treats:Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
Indications and Usage:16 Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: * Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. (1.1) * Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. (1.2)
DrugBank Targets: -
Mechanism of Action:16 
Target: soluble guanylate cyclase (sGC)
Action: stimulator
FDA: Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation.Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding. Riociguat also directly stimulates sGC via a different binding site, independently of NO. Riociguat stimulates the NO-sGC-cGMP pathway and leads to increased generation of cGMP with subsequent vasodilation. The active metabolite (M1) of riociguat is 1/3 to 1/10 as potent as riociguat.
17
Vibativ16 * TELAVANCIN * TELAVANCIN HYDROCHLORIDE Theravance June 2013
FDA Label: Vibativ
Disease/s that Drug Treats:hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus
Indications and Usage:16 VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: * Complicated skin and skin structure infections (cSSSI) (1.1) * Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus. VIBATIV should be reserved for use when alternative treatments are not suitable. (1.2)
DrugBank Targets: -
Mechanism of Action:16 
Target: late-stage peptidoglycan precursors
Action: inhibits cell wall biosynthesis
FDA: Telavancin is an antibacterial drug [see Clinical Pharmacology (12.4)]. Telavancin inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II. Telavancin also binds to the bacterial membrane and disrupts membrane barrier function.

Drugs for Multiple Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 684)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
VidarabineapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 152124356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
2
Dexamethasoneapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1217150-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
3
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
4
EpirubicinapprovedPhase 4, Phase 3, Phase 239456420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
5
FludarabineapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1115421679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
6
Doxorubicinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
7
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
8
Busulfanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 154555-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
9
Bortezomibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1807179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
10
LenalidomideapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1736191732-72-6216326
Synonyms:
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
191732-72-6
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
346670-73-3
443912-14-9
AC-914
AC1L50II
AKOS005146276
ALBB-015321
Bio-0168
C467567
CC 5013
CC-5013
CC-5013, Revlimid, Lenalidomide
CC5013
CDC 501
CDC-501
CDC-5013
CHEMBL848
CID216326
Celgene brand of lenalidomide
D04687
 
DB00480
EC-000.2340
ENMD-0997
I06-0831
IMID-1
IMID-5013
IMiD3
IMiD3 cpd
IMid-1
LS-184040
Lenalidomide
Lenalidomide (USAN/INN)
Lenalidomide [USAN]
MolPort-003-848-370
NCGC00167491-01
NSC747972
Revamid
Revimid
Revlimid
Revlimid (Celgene)
Revlimid (TN)
S1029_Selleck
STK639603
Thalidomide analog CC-5013
UNII-F0P408N6V4
lenalidomide
11
Panobinostatapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 2135404950-80-76918837
Synonyms:
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
404950-80-7
AC1OCFY8
AKOS005146046
C496932
CHEMBL483254
CID6918837
EC-000.2287
FT-0083488
Faridak
 
LBH 589
LBH-589
LBH-589B
LBH589
MolPort-005-933-338
NVP-LBH-589
NVP-LBH589
Panobinostat
Panobinostat, NVP-LBH589, LBH589
S1030_Selleck
ZINC22010649
nchembio.313-comp11
panobinostat
12
IronapprovedPhase 4, Phase 3, Phase 2, Phase 111657439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
13
MesnaapprovedPhase 4, Phase 3, Phase 2, Phase 12633375-50-6598
Synonyms:
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-mercaptoethanesulfonic acid
2-mercaptoethanesulphonic acid
2-mercaptoethylsulfonate
2-sulfanylethylsulfonate
 
CoM
Coenzima M
Coenzym M
Coenzyme M
HS-CoM
reduced CoM
reduced coenzyme M
β-mercaptoethanesulfonic acid
14
Prednisoneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
15
MelphalanapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1729148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
16
Zoledronic acidapprovedPhase 4, Phase 3, Phase 2, Phase 1294118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
DB00399
 
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zol
Zoledronate
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
17
ThiotepaapprovedPhase 4, Phase 2, Phase 122652-24-45453
Synonyms:
 
Thioplex
18
PiperacillinapprovedPhase 4, Phase 310166258-76-243672
Synonyms:
(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
4-ethyl-2,3-dioxopiperazine carbonyl ampicillin
59703-84-3
59703-84-3 (mono-hydrochloride salt)
6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid
61477-96-1
6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid
AC1L2ACR
AC1Q5QXJ
BIDD:GT0167
BPBio1_000848
BRD-K86873305-236-03-0
BSPBio_000770
C14034
C23H27N5O7S
CCRIS 7362
CHEBI:8232
CHEMBL702
CID43672
Cl-227193
D08380
EINECS 262-811-8
HMS2090H19
LS-149794
 
PIPC
PIPERACILLIN SODIUM
Peperacillin
Peracin
Peracin (TN)
Piperacilina
Piperacillin
Piperacillin (INN)
Piperacillin (anhydrous)
Piperacillin Anhydrous
Piperacillin Monosodium Salt
Piperacillin anhydrous
Piperacillina
Piperacillinum
Pipercillin
Pipracil
Pipracil, Piper
Pipril
Pipéracilline
Prestwick0_000755
Prestwick1_000755
Prestwick2_000755
Prestwick3_000755
SPBio_002709
T-1220
UNII-9I628532GX
piperacillin
19
TazobactamapprovedPhase 4, Phase 310389786-04-9123630
Synonyms:
(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4
(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
89785-84-2
89786-04-9
AC-7620
AC1L3X07
BIDD:GT0212
C07771
CHEBI:100207
CHEMBL404
 
CID123630
CL-298741
CL298741
D00660
DB01606
MolPort-002-500-123
TAZ
Tazobactam
Tazobactam (JAN/USAN/INN)
YTR-830H
YTR830H
20
PhentolamineapprovedPhase 42250-60-25775
Synonyms:
2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline
2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline
2-(N-(m-Hydroxyphenyl)-P-toluidinomethyl)imidazoline
2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline
2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline
3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol
5-25-09-00365 (Beilstein Handbook Reference)
50-60-2
65-28-1 (mesylate (salt))
73-05-2 (mono-hydrochloride)
AC1L1L3Z
AC1Q2KIW
AKOS004119917
BCBcMAP01_000014
BPBio1_000307
BRD-K90333595-001-02-8
BRD-K90333595-003-04-0
BRN 0272944
BSPBio_000279
BSPBio_001435
BSPBio_002496
C 7337
C 7337 Ciba
C17H19N3O
CAS-73-05-2
CHEBI:120131
CHEMBL597
CID5775
D08362
DB00692
Dibasin
DivK1c_000807
EINECS 200-053-1
Fentolamin
Fentolamina
Fentolamina [INN-Spanish]
HMS1791H17
HMS1989H17
HMS2089E03
HSDB 3382
IDI1_000807
KBio1_000807
KBio2_000477
KBio2_003045
KBio2_005613
KBio3_001716
KBioGR_001338
KBioSS_000477
 
L001116
LS-104396
Lopac0_000982
MLS000040874
MLS001201741
MolPort-001-783-569
NCGC00016311-01
NCGC00016311-02
NCGC00016311-03
NCGC00016311-15
NCGC00021804-06
NCGC00021804-07
NCGC00021804-08
NCGC00021804-09
NCGC00021804-10
NINDS_000807
Phenotolamine
Phentalamine
Phentolamin
Phentolamine
Phentolamine (INN)
Phentolamine [INN:BAN]
Phentolamine mesylate
Phentolamine mesylate [USAN]
Phentolamine methanesulfonate
Phentolamine, methyl sulfonate
Phentolaminum
Phentolaminum [INN-Latin]
Prestwick0_000230
Prestwick1_000230
Prestwick2_000230
Prestwick3_000230
Regitin
Regitina
Regitine
Regitipe
Regityn
Rogitine
SMP1_000236
SMR000058051
SPBio_002200
STK802099
STOCK4S-00358
Spectrum3_000788
Spectrum4_000899
Spectrum5_001704
Spectrum_000077
UNII-Z468598HBV
Vesomax
nchembio705-6
phentolamine
21
ApixabanapprovedPhase 4, Phase 3, Phase 2154503612-47-310182969
Synonyms:
1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd
2p16
503612-47-3
AKOS005146204
Apixaban
Apixaban (JAN/USAN/INN)
BMS 562247-01
BMS-562247
BMS-562247-01
BMS-562247-01, Apixaban
 
CHEBI:49620
CHEMBL231779
CID10182969
D03213
DB07828
GG2
S1593_Selleck
UNII-3Z9Y7UWC1J
apixabanum
apixabán
ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide
22
LiraglutideapprovedPhase 4329204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
23
PirarubicininvestigationalPhase 42272496-41-4
Synonyms:
Adriamycin, tetrahydropyranyl
 
THP-Adm
THP-Doxorubicin
Theprubicin
24
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1175131703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
25Epoetin alfaPhase 4, Phase 3, Phase 2658113427-24-0
26Proteasome InhibitorsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 197
27Adjuvants, ImmunologicPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 12554
28HematinicsPhase 4, Phase 3, Phase 21684
29AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112054
30AnticoagulantsPhase 4, Phase 3, Phase 2, Phase 12623
31AntibodiesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16394
32Hypoglycemic AgentsPhase 4, Phase 1, Phase 25896
33ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16394
34Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 17361
35Antilymphocyte SerumPhase 4, Phase 2, Phase 3, Phase 1408
36Anti-Retroviral AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13296
37Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 19967
38JM 3100Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1135
39Anti-HIV AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13162
40Bone Density Conservation AgentsPhase 4, Phase 3, Phase 2, Phase 13376
41glucocorticoidsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15103
42Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 18402
43Dexamethasone acetatePhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121711177-87-3
44HIV Protease InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15470
45Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113180
46Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113168
47HormonesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 114415
48Dexamethasone 21-phosphatePhase 4, Phase 3, Phase 2, Phase 1, Early Phase 12171
49BB 1101Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 12171
50Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110729

Interventional clinical trials:

(show top 50)    (show all 2294)
idNameStatusNCT IDPhase
1Stage I Multiple Myeloma TreatmentUnknown statusNCT00733538Phase 4
2A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple MyelomaUnknown statusNCT01868828Phase 4
3Efficacy Study of PAD and TAD in Newly Diagnosed Multiple MyelomaUnknown statusNCT01249690Phase 4
4Pseudohyponatremia of Multiple Myeloma is True HyponatremiaUnknown statusNCT01425606Phase 4
5Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaCompletedNCT02559583Phase 4
6Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple MyelomaCompletedNCT01083602Phase 4
7A Multiple Myeloma Trial in Patients With Bone MetastasesCompletedNCT00104104Phase 4
8A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple MyelomaCompletedNCT02268890Phase 4
9Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple MyelomaCompletedNCT00652041Phase 4
10Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma PatientsCompletedNCT00622505Phase 4
11Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early BortezomibCompletedNCT01060202Phase 4
12A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any ProcedureCompletedNCT01241396Phase 4
13Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.CompletedNCT01026701Phase 4
14Quality of Life in Multiple Myeloma Patients Treated With BortezomibCompletedNCT01021592Phase 4
15A Retreatment Study With Bortezomib for Multiple MyelomaCompletedNCT01030302Phase 4
16Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple MyelomaCompletedNCT02474563Phase 4
17Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and TolerabilityCompletedNCT00257114Phase 4
18Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone LesionsCompletedNCT00029224Phase 4
19An Observational Study of Chinese Multiple Myeloma Patients Treated With VelcadeCompletedNCT01675245Phase 4
20REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERsCompletedNCT02950389Phase 4
21VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the NetherlandsCompletedNCT00440765Phase 4
22ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.CompletedNCT00440479Phase 4
23Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)CompletedNCT01005628Phase 4
24PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC TransplantationCompletedNCT00352703Phase 4
25Retrospective Survey of Re-treatment With BortezomibCompletedNCT01524445Phase 4
26Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving ChemotherapyCompletedNCT00524407Phase 4
27Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone MetastasesCompletedNCT00434447Phase 4
28Clinical And Economic Impact Of Upfront Plerixafor In Autologous TransplantationCompletedNCT01339572Phase 4
29FREE Study - Fracture Reduction EvaluationCompletedNCT00211211Phase 4
30Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic PatientsCompletedNCT00195533Phase 4
31Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
32Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous TransplantationCompletedNCT01738373Phase 4
33Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)CompletedNCT00361140Phase 4
34CAFE Study - Cancer Patient Fracture EvaluationCompletedNCT00211237Phase 4
35Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple MyelomaRecruitingNCT02773550Phase 4
36Modified Bortezomib-based Combination Therapy for Multiple MyelomaRecruitingNCT02559154Phase 4
37Prolonged Protection From Bone Disease in Multiple MyelomaRecruitingNCT02286830Phase 4
38PDD vs PAD to Treat Initially Diagnosed MMRecruitingNCT02577783Phase 4
39Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical RelapseActive, not recruitingNCT01087008Phase 4
40Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple MyelomaActive, not recruitingNCT01731886Phase 4
41Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple MyelomaNot yet recruitingNCT02958969Phase 4
42An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (TOURMALINE MM-6)Not yet recruitingNCT03173092Phase 4
43Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.Not yet recruitingNCT02006225Phase 4
44Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial FatNot yet recruitingNCT02920190Phase 4
45Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving ChemotherapyTerminatedNCT01100879Phase 4
46A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin BTerminatedNCT02608060Phase 4
47Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.WithdrawnNCT00242528Phase 4
48Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple MyelomaWithdrawnNCT01410929Phase 4
49Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple MyelomaUnknown statusNCT00002653Phase 3
50Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple MyelomaUnknown statusNCT00014339Phase 3

Search NIH Clinical Center for Multiple Myeloma

Inferred drug relations via UMLS68/NDF-RT46:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Multiple Myeloma cell therapies at LifeMap Discovery.

Genetic Tests for Multiple Myeloma

About this section

Genetic tests related to Multiple Myeloma:

id Genetic test Affiliating Genes
1 Multiple Myeloma27 24 LIG4

Anatomical Context for Multiple Myeloma

About this section

MalaCards organs/tissues related to Multiple Myeloma:

36
Bone, Bone marrow, Testes, T cells, B cells, Myeloid, Endothelial

FMA organs/tissues related to Multiple Myeloma:

17
The plasma cells in bone marrow

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Multiple Myeloma:
id TissueAnatomical CompartmentCell Relevance
1 BloodHematopoietic Bone MarrowHematopoietic Stem Cells Potential therapeutic candidate
2 BloodPeripheral BloodMature B-Cells Affected by disease

Publications for Multiple Myeloma

About this section

Articles related to Multiple Myeloma:

(show top 50)    (show all 3441)
idTitleAuthorsYear
1
The effect of S1P receptor signaling pathway on the survival and drug resistance in multiple myeloma cells. (27785703)
2017
2
Asymmetric Deep Stromal Keratopathy in a Patient With Multiple Myeloma. (28079685)
2017
3
The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient. (28381753)
2017
4
Racial disparities in treatment use for multiple myeloma. (28085188)
2017
5
Inhibiting the osteocyte specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. (28515094)
2017
6
Current Strategies for the Immunotherapy of Multiple Myeloma. (28090624)
2017
7
NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase. (28086949)
2017
8
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma. (28083618)
2017
9
A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. (28088784)
2017
10
Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma. (28527129)
2017
11
Identification of a novel microRNA, miR-4449, as a potential blood based marker in multiple myeloma. (27155004)
2017
12
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. (28082445)
2017
13
Disappearance of acquired hemophilia A after complete remission in a Multiple Myeloma patient. (28077343)
2017
14
Identification of precision treatment strategies for relapsed/ refractory multiple myeloma by functional drug sensitivity testing. (28525891)
2017
15
Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China. (28091402)
2017
16
Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma. (27677741)
2017
17
Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture. (28512409)
2017
18
RGS1 expression is associated with poor prognosis in multiple myeloma. (27445341)
2017
19
MicroRNA-1271 inhibits proliferation and promotes apoptosis of multiple myeloma cells through inhibiting smoothened-mediated Hedgehog signaling pathway. (27959416)
2017
20
Risk of vertebral compression fractures in multiple myeloma patients: A finite-element study. (28079810)
2017
21
G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. (28509594)
2017
22
Return to the Primary Acute Care Service Among Patients With Multiple Myeloma on an Acute Inpatient Rehabilitation Unit. (28082181)
2017
23
Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study. (28535102)
2017
24
Dermoscopy of cutaneous involvement by multiple myeloma. (28087038)
2017
25
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. (28513828)
2017
26
Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. (28085010)
2017
27
Crohn's disease and smoldering multiple myeloma: a case report and literature review. (28522957)
2017
28
Utilizing next-generation sequencing in the management of multiple myeloma. (28524737)
2017
29
Genetic deletion of sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. (28529307)
2017
30
EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma. (28351297)
2017
31
bFGF Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients. (28373444)
2017
32
RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. (27909306)
2017
33
Immunoglobulin A Lambda Multiple Myeloma in a Patient with HIV: An Unusual Cause of Massive Ascites. (28512393)
2017
34
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). (28534173)
2017
35
Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. (28068938)
2017
36
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. (28529638)
2017
37
A family-centered intervention for the transition to living with multiple myeloma as a chronic illness: A pilot study. (28532734)
2017
38
hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. (28000886)
2017
39
Is immunotherapy here to stay in multiple myeloma? (28082344)
2017
40
New Treatment Options for the Management of Multiple Myeloma. (28515251)
2017
41
Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation. (28512269)
2017
42
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. (28522572)
2017
43
Haematological cancer: Pembrolizumab is effective in multiple myeloma. (28534530)
2017
44
Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. (28521480)
2017
45
Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. (28063964)
2017
46
Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience. (28091419)
2017
47
Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma. (26033514)
2017
48
Carfilzomib, lenalidomide, and dexamethasone in patients with heavily-pretreated multiple myeloma: A phase 1 study in Japan. (28092421)
2017
49
Effect of Cytokine Genes in the Pathogenesis and on the Clinical Parameters for the Treatment of Multiple Myeloma. (27611810)
2017
50
Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants in multiple myeloma. (28522109)
2017

Variations for Multiple Myeloma

About this section

Clinvar genetic disease variations for Multiple Myeloma:

5 (show all 132)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_ 000546.5(TP53): c.742C> T (p.Arg248Trp)SNVPathogenic/ Likely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
2TP53NM_ 000546.5(TP53): c.743G> A (p.Arg248Gln)SNVPathogenic/ Likely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
3TP53NM_ 000546.5(TP53): c.818G> A (p.Arg273His)SNVPathogenic/ Likely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
4TP53NM_ 000546.5(TP53): c.451C> A (p.Pro151Thr)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
5TP53NM_ 000546.5(TP53): c.451C> T (p.Pro151Ser)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
6HRASNM_ 005343.3(HRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
7HRASNM_ 005343.3(HRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs104894230GRCh37Chr 11, 534288: 534288
8HRASNM_ 005343.3(HRAS): c.37G> T (p.Gly13Cys)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
9HRASNM_ 005343.3(HRAS): c.436G> A (p.Ala146Thr)SNVPathogenic/ Likely pathogenicrs104894231GRCh37Chr 11, 533467: 533467
10HRASNM_ 005343.3(HRAS): c.437C> T (p.Ala146Val)SNVPathogenic/ Likely pathogenicrs121917759GRCh37Chr 11, 533466: 533466
11HRASNM_ 005343.3(HRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
12PTPN11NM_ 002834.4(PTPN11): c.226G> A (p.Glu76Lys)SNVPathogenic/ Likely pathogenicrs121918464GRCh37Chr 12, 112888210: 112888210
13PTPN11NM_ 002834.4(PTPN11): c.227A> G (p.Glu76Gly)SNVPathogenic/ Likely pathogenicrs121918465GRCh37Chr 12, 112888211: 112888211
14PTPN11NM_ 002834.4(PTPN11): c.227A> C (p.Glu76Ala)SNVPathogenic/ Likely pathogenicrs121918465GRCh37Chr 12, 112888211: 112888211
15NRASNM_ 002524.4(NRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs121434595GRCh37Chr 1, 115258745: 115258745
16NRASNM_ 002524.4(NRAS): c.182A> G (p.Gln61Arg)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
17NRASNM_ 002524.4(NRAS): c.38G> A (p.Gly13Asp)SNVPathogenic/ Likely pathogenicrs121434596GRCh37Chr 1, 115258744: 115258744
18BRAFNM_ 004333.4(BRAF): c.1799T> A (p.Val600Glu)SNVPathogenic/ Likely pathogenicrs113488022GRCh37Chr 7, 140453136: 140453136
19BRAFNM_ 004333.4(BRAF): c.1397G> T (p.Gly466Val)SNVPathogenic/ Likely pathogenicrs121913351GRCh37Chr 7, 140481411: 140481411
20BRAFNM_ 004333.4(BRAF): c.1790T> G (p.Leu597Arg)SNVPathogenic/ Likely pathogenicrs121913366GRCh37Chr 7, 140453145: 140453145
21BRAFNM_ 004333.4(BRAF): c.1405G> C (p.Gly469Arg)SNVPathogenic/ Likely pathogenicrs121913357GRCh37Chr 7, 140481403: 140481403
22BRAFNM_ 004333.4(BRAF): c.1406G> C (p.Gly469Ala)SNVPathogenic/ Likely pathogenicrs121913355GRCh37Chr 7, 140481402: 140481402
23BRAFNM_ 004333.4(BRAF): c.1781A> G (p.Asp594Gly)SNVPathogenic/ Likely pathogenicrs121913338GRCh37Chr 7, 140453154: 140453154
24BRAFNM_ 004333.4(BRAF): c.1406G> A (p.Gly469Glu)SNVPathogenic/ Likely pathogenicrs121913355GRCh37Chr 7, 140481402: 140481402
25TP53NM_ 000546.5(TP53): c.422G> A (p.Cys141Tyr)SNVPathogenic/ Likely pathogenicrs587781288GRCh37Chr 17, 7578508: 7578508
26TP53NM_ 000546.5(TP53): c.842A> G (p.Asp281Gly)SNVPathogenic/ Likely pathogenicrs587781525GRCh37Chr 17, 7577096: 7577096
27IDH2NM_ 002168.3(IDH2): c.419G> A (p.Arg140Gln)SNVPathogenic/ Likely pathogenicrs121913502GRCh37Chr 15, 90631934: 90631934
28IDH1NM_ 001282386.1(IDH1): c.395G> A (p.Arg132His)SNVPathogenic/ Likely pathogenicrs121913500GRCh38Chr 2, 208248388: 208248388
29FGFR3NM_ 000142.4(FGFR3): c.1948A> G (p.Lys650Glu)SNVPathogenic/ Likely pathogenicrs78311289GRCh37Chr 4, 1807889: 1807889
30FGFR3NM_ 000142.4(FGFR3): c.742C> T (p.Arg248Cys)SNVPathogenic/ Likely pathogenicrs121913482GRCh37Chr 4, 1803564: 1803564
31FGFR3FGFR3, FGFR3/IGH FUSIONundetermined variantPathogenic
32CDK4NM_ 000075.3(CDK4): c.70C> T (p.Arg24Cys)SNVPathogenic/ Likely pathogenic, risk factorrs11547328GRCh37Chr 12, 58145431: 58145431
33CDK4NM_ 000075.3(CDK4): c.71G> A (p.Arg24His)SNVLikely pathogenic, risk factorrs104894340GRCh37Chr 12, 58145430: 58145430
34BRAFNM_ 004333.4(BRAF): c.1742A> G (p.Asn581Ser)SNVLikely pathogenicrs121913370GRCh37Chr 7, 140453193: 140453193
35NRASNM_ 002524.4(NRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
36HRASNM_ 005343.3(HRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs104894226GRCh38Chr 11, 534285: 534285
37TP53NM_ 000546.5(TP53): c.842A> T (p.Asp281Val)SNVPathogenic/ Likely pathogenicrs587781525GRCh38Chr 17, 7673778: 7673778
38TP53NM_ 000546.5(TP53): c.824G> A (p.Cys275Tyr)SNVPathogenic/ Likely pathogenicrs863224451GRCh38Chr 17, 7673796: 7673796
39TP53NM_ 000546.5(TP53): c.584T> C (p.Ile195Thr)SNVPathogenic/ Likely pathogenicrs760043106GRCh38Chr 17, 7674947: 7674947
40NRASNM_ 002524.4(NRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs121913237GRCh38Chr 1, 114716126: 114716126
41TP53NM_ 000546.5(TP53): c.743G> T (p.Arg248Leu)SNVLikely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
42TP53NM_ 000546.5(TP53): c.818G> C (p.Arg273Pro)SNVLikely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
43TP53NM_ 000546.5(TP53): c.587G> C (p.Arg196Pro)SNVLikely pathogenicrs483352697GRCh37Chr 17, 7578262: 7578262
44TP53NM_ 000546.5(TP53): c.833C> T (p.Pro278Leu)SNVPathogenic/ Likely pathogenicrs876659802GRCh37Chr 17, 7577105: 7577105
45TP53NM_ 000546.5(TP53): c.743G> C (p.Arg248Pro)SNVLikely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
46NRASNM_ 002524.4(NRAS): c.182A> C (p.Gln61Pro)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
47HRASNM_ 005343.3(HRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
48MYD88NM_ 001172567.1(MYD88): c.818T> C (p.Leu273Pro)SNVPathogenic/ Likely pathogenicrs387907272GRCh37Chr 3, 38182641: 38182641
49NRASNM_ 002524.4(NRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs121913255GRCh37Chr 1, 115256528: 115256528
50NRASNM_ 002524.4(NRAS): c.182A> T (p.Gln61Leu)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
51NRASNM_ 002524.4(NRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs121434596GRCh37Chr 1, 115258744: 115258744
52IDH1NM_ 005896.3(IDH1): c.395G> T (p.Arg132Leu)SNVPathogenic/ Likely pathogenicrs121913500GRCh37Chr 2, 209113112: 209113112
53IDH1NM_ 001282387.1(IDH1): c.394C> T (p.Arg132Cys)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
54IDH1NM_ 001282387.1(IDH1): c.394C> G (p.Arg132Gly)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
55IDH1NM_ 001282387.1(IDH1): c.394C> A (p.Arg132Ser)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
56BRAFNM_ 004333.4(BRAF): c.1786G> C (p.Gly596Arg)SNVPathogenic/ Likely pathogenicrs121913361GRCh38Chr 7, 140753349: 140753349
57BRAFNM_ 004333.4(BRAF): c.1780G> C (p.Asp594His)SNVPathogenic/ Likely pathogenicrs397516896GRCh37Chr 7, 140453155: 140453155
58KRASNM_ 004985.4(KRAS): c.351A> C (p.Lys117Asn)SNVPathogenic/ Likely pathogenicrs770248150GRCh37Chr 12, 25378647: 25378647
59IDH2NM_ 002168.3(IDH2): c.419G> T (p.Arg140Leu)SNVPathogenic/ Likely pathogenicrs121913502GRCh37Chr 15, 90631934: 90631934
60IDH2NM_ 002168.3(IDH2): c.418C> T (p.Arg140Trp)SNVPathogenic/ Likely pathogenicrs267606870GRCh37Chr 15, 90631935: 90631935
61HRAS; LRRC56NM_ 005343.3(HRAS): c.182A> T (p.Gln61Leu)SNVLikely pathogenicrs121913233GRCh37Chr 11, 533874: 533874
62BRAFNM_ 004333.4(BRAF): c.1397G> A (p.Gly466Glu)SNVLikely pathogenicrs121913351GRCh37Chr 7, 140481411: 140481411
63BRAFNM_ 004333.4(BRAF): c.1397G> C (p.Gly466Ala)SNVLikely pathogenicrs121913351GRCh37Chr 7, 140481411: 140481411
64HRAS; LRRC56NM_ 005343.3(HRAS): c.182A> C (p.Gln61Pro)SNVLikely pathogenicrs121913233GRCh37Chr 11, 533874: 533874
65B2MNM_ 004048.2(B2M): c.3G> A (p.Met1Ile)SNVLikely pathogenicrs1057519877GRCh37Chr 15, 45003747: 45003747
66B2MNM_ 004048.2(B2M): c.1A> G (p.Met1Val)SNVLikely pathogenicrs1023835002GRCh37Chr 15, 45003745: 45003745
67B2MNM_ 004048.2(B2M): c.1A> T (p.Met1Leu)SNVLikely pathogenicrs1023835002GRCh37Chr 15, 45003745: 45003745
68B2MNM_ 004048.2(B2M): c.2T> C (p.Met1Thr)SNVLikely pathogenicrs1057519879GRCh37Chr 15, 45003746: 45003746
69B2MNM_ 004048.2(B2M): c.2T> G (p.Met1Arg)SNVLikely pathogenicrs1057519879GRCh37Chr 15, 45003746: 45003746
70BRAFNM_ 004333.4(BRAF): c.1786G> A (p.Gly596Ser)SNVLikely pathogenicrs121913361GRCh37Chr 7, 140453149: 140453149
71BRAFNM_ 004333.4(BRAF): c.1787G> A (p.Gly596Asp)SNVLikely pathogenicrs397507483GRCh37Chr 7, 140453148: 140453148
72BRAFNM_ 004333.4(BRAF): c.1742A> C (p.Asn581Thr)SNVLikely pathogenicrs121913370GRCh38Chr 7, 140753393: 140753393
73CDK4NM_ 000075.3(CDK4): c.71G> T (p.Arg24Leu)SNVLikely pathogenicrs104894340GRCh37Chr 12, 58145430: 58145430
74CDK4NM_ 000075.3(CDK4): c.70C> A (p.Arg24Ser)SNVLikely pathogenicrs11547328GRCh37Chr 12, 58145431: 58145431
75HRAS; LRRC56NM_ 005343.3(HRAS): c.436G> C (p.Ala146Pro)SNVLikely pathogenicrs104894231GRCh37Chr 11, 533467: 533467
76HRAS; LRRC56NM_ 005343.3(HRAS): c.38G> C (p.Gly13Ala)SNVLikely pathogenicrs104894226GRCh37Chr 11, 534285: 534285
77HRAS; LRRC56NM_ 005343.3(HRAS): c.181C> G (p.Gln61Glu)SNVLikely pathogenicrs28933406GRCh38Chr 11, 533875: 533875
78PIK3CANM_ 006218.3(PIK3CA): c.331A> G (p.Lys111Glu)SNVLikely pathogenicrs1057519933GRCh37Chr 3, 178916944: 178916944
79PIK3CANM_ 006218.3(PIK3CA): c.333G> C (p.Lys111Asn)SNVLikely pathogenicrs1057519934GRCh37Chr 3, 178916946: 178916946
80PIK3CANM_ 006218.3(PIK3CA): c.332A> G (p.Lys111Arg)SNVLikely pathogenicrs1057519935GRCh37Chr 3, 178916945: 178916945
81TP53NM_ 001126113.2(TP53): c.421T> C (p.Cys141Arg)SNVLikely pathogenicrs1057519978GRCh37Chr 17, 7578509: 7578509
82TP53NM_ 001126115.1(TP53): c.25T> G (p.Cys9Gly)SNVLikely pathogenicrs1057519978GRCh37Chr 17, 7578509: 7578509
83TP53NM_ 000546.5(TP53): c.421T> A (p.Cys141Ser)SNVLikely pathogenicrs1057519978GRCh37Chr 17, 7578509: 7578509
84TP53NM_ 001126114.2(TP53): c.422G> T (p.Cys141Phe)SNVLikely pathogenicrs587781288GRCh37Chr 17, 7578508: 7578508
85TP53NM_ 000546.5(TP53): c.713G> T (p.Cys238Phe)SNVPathogenic/ Likely pathogenicrs730882005GRCh37Chr 17, 7577568: 7577568
86TP53NM_ 000546.5(TP53): c.713G> C (p.Cys238Ser)SNVLikely pathogenicrs730882005GRCh37Chr 17, 7577568: 7577568
87TP53NM_ 001126117.1(TP53): c.316T> C (p.Cys106Arg)SNVLikely pathogenicrs1057519981GRCh37Chr 17, 7577569: 7577569
88TP53NM_ 001126115.1(TP53): c.316T> G (p.Cys106Gly)SNVLikely pathogenicrs1057519981GRCh37Chr 17, 7577569: 7577569
89TP53NM_ 001126117.1(TP53): c.428G> T (p.Cys143Phe)SNVLikely pathogenicrs863224451GRCh37Chr 17, 7577114: 7577114
90TP53NM_ 001126112.2(TP53): c.824G> C (p.Cys275Ser)SNVLikely pathogenicrs863224451GRCh37Chr 17, 7577114: 7577114
91TP53NM_ 001126112.2(TP53): c.823T> C (p.Cys275Arg)SNVLikely pathogenicrs1057519983GRCh37Chr 17, 7577115: 7577115
92TP53NM_ 001126116.1(TP53): c.445G> T (p.Asp149Tyr)SNVLikely pathogenicrs764146326GRCh37Chr 17, 7577097: 7577097
93TP53NM_ 001126116.1(TP53): c.445G> A (p.Asp149Asn)SNVLikely pathogenicrs764146326GRCh37Chr 17, 7577097: 7577097
94TP53NM_ 001126117.1(TP53): c.447C> G (p.Asp149Glu)SNVLikely pathogenicrs1057519984GRCh37Chr 17, 7577095: 7577095
95TP53NM_ 001126115.1(TP53): c.445G> C (p.Asp149His)SNVLikely pathogenicrs764146326GRCh37Chr 17, 7577097: 7577097
96TP53NM_ 001126117.1(TP53): c.446A> C (p.Asp149Ala)SNVLikely pathogenicrs587781525GRCh37Chr 17, 7577096: 7577096
97TP53NM_ 001126115.1(TP53): c.187A> T (p.Ile63Phe)SNVLikely pathogenicrs942158624GRCh37Chr 17, 7578266: 7578266
98TP53NM_ 001126118.1(TP53): c.467T> A (p.Ile156Asn)SNVLikely pathogenicrs760043106GRCh37Chr 17, 7578265: 7578265
99TP53NM_ 001126116.1(TP53): c.188T> G (p.Ile63Ser)SNVLikely pathogenicrs760043106GRCh37Chr 17, 7578265: 7578265
100TP53NM_ 001126116.1(TP53): c.189C> G (p.Ile63Met)SNVLikely pathogenicrs1057519994GRCh37Chr 17, 7578264: 7578264
101TP53NM_ 000546.5(TP53): c.396G> C (p.Lys132Asn)SNVLikely pathogenicrs866775781GRCh37Chr 17, 7578534: 7578534
102TP53NM_ 001126112.2(TP53): c.395A> C (p.Lys132Thr)SNVLikely pathogenicrs1057519996GRCh37Chr 17, 7578535: 7578535
103TP53NM_ 001126112.2(TP53): c.394A> C (p.Lys132Gln)SNVLikely pathogenicrs747342068GRCh37Chr 17, 7578536: 7578536
104TP53NM_ 000546.5(TP53): c.395A> T (p.Lys132Met)SNVLikely pathogenicrs1057519996GRCh37Chr 17, 7578535: 7578535
105TP53NM_ 001126112.2(TP53): c.452C> A (p.Pro151His)SNVLikely pathogenicrs1057520000GRCh37Chr 17, 7578478: 7578478
106TP53NM_ 001126115.1(TP53): c.56C> G (p.Pro19Arg)SNVLikely pathogenicrs1057520000GRCh37Chr 17, 7578478: 7578478
107TP53NM_ 001126115.1(TP53): c.436C> T (p.Pro146Ser)SNVLikely pathogenicrs17849781GRCh37Chr 17, 7577106: 7577106
108TP53NM_ 001126117.1(TP53): c.436C> A (p.Pro146Thr)SNVLikely pathogenicrs17849781GRCh37Chr 17, 7577106: 7577106
109TP53NM_ 001126114.2(TP53): c.833C> G (p.Pro278Arg)SNVLikely pathogenicrs876659802GRCh37Chr 17, 7577105: 7577105
110TP53NM_ 001126114.2(TP53): c.832C> G (p.Pro278Ala)SNVLikely pathogenicrs17849781GRCh37Chr 17, 7577106: 7577106
111TP53NM_ 000546.5(TP53): c.833C> A (p.Pro278His)SNVLikely pathogenicrs876659802GRCh37Chr 17, 7577105: 7577105
112TP53NM_ 000546.5(TP53): c.742C> G (p.Arg248Gly)SNVLikely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
113TP53NM_ 001126112.2(TP53): c.818G> T (p.Arg273Leu)SNVLikely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
114TP53NM_ 001126112.2(TP53): c.817C> A (p.Arg273Ser)SNVLikely pathogenicrs121913343GRCh37Chr 17, 7577121: 7577121
115TP53NM_ 001126116.1(TP53): c.419T> A (p.Val140Glu)SNVLikely pathogenicrs876660333GRCh37Chr 17, 7577123: 7577123
116TP53NM_ 001126118.1(TP53): c.497A> G (p.Tyr166Cys)SNVLikely pathogenicrs1057520007GRCh37Chr 17, 7578235: 7578235
117TP53NM_ 001126117.1(TP53): c.218A> T (p.Tyr73Phe)SNVLikely pathogenicrs1057520007GRCh37Chr 17, 7578235: 7578235
118TP53NM_ 001126118.1(TP53): c.497A> C (p.Tyr166Ser)SNVLikely pathogenicrs1057520007GRCh37Chr 17, 7578235: 7578235
119TP53NM_ 001126113.2(TP53): c.613T> A (p.Tyr205Asn)SNVLikely pathogenicrs1057520008GRCh37Chr 17, 7578236: 7578236
120TP53NM_ 000546.5(TP53): c.613T> C (p.Tyr205His)SNVLikely pathogenicrs1057520008GRCh37Chr 17, 7578236: 7578236
121NRASNM_ 002524.4(NRAS): c.35G> A (p.Gly12Asp)SNVPathogenic/ Likely pathogenicrs121913237GRCh37Chr 1, 115258747: 115258747
122BRAFNM_ 004333.4(BRAF): c.1787G> T (p.Gly596Val)SNVPathogenic/ Likely pathogenicrs397507483GRCh37Chr 7, 140453148: 140453148
123NRASNM_ 002524.4(NRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
124NRASNM_ 002524.4(NRAS): c.34G> C (p.Gly12Arg)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
125NRASNM_ 002524.4(NRAS): c.35G> T (p.Gly12Val)SNVPathogenic/ Likely pathogenicrs121913237GRCh37Chr 1, 115258747: 115258747
126PTPN11NM_ 002834.4(PTPN11): c.1508G> T (p.Gly503Val)SNVLikely pathogenicrs397507546GRCh37Chr 12, 112926888: 112926888
127BRAFNM_ 004333.4(BRAF): c.1406G> T (p.Gly469Val)SNVPathogenic/ Likely pathogenicrs121913355GRCh37Chr 7, 140481402: 140481402
128BRAFNM_ 004333.4(BRAF): c.1780G> A (p.Asp594Asn)SNVPathogenic/ Likely pathogenicrs397516896GRCh37Chr 7, 140453155: 140453155
129KRASNM_ 033360.3(KRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs17851045GRCh37Chr 12, 25380275: 25380275
130BRAFNM_ 004333.4(BRAF): c.1741A> C (p.Asn581His)SNVLikely pathogenicrs180177040GRCh37Chr 7, 140453987: 140453987
131NRASNM_ 002524.4(NRAS): c.181C> A (p.Gln61Lys)SNVPathogenic/ Likely pathogenicrs121913254GRCh37Chr 1, 115256530: 115256530
132BRAFNM_ 004333.4(BRAF): c.1790T> A (p.Leu597Gln)SNVPathogenic/ Likely pathogenicrs121913366GRCh37Chr 7, 140453145: 140453145

Copy number variations for Multiple Myeloma from CNVD:

6 (show top 50)    (show all 302)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
11335111125000000GainMultiple myeloma
2140611103799708118390708LossMultiple myeloma
3143381107200000120600000Loss and deletionMultiple myeloma
4146961110000000184000000GainSELLMultiple myeloma
5164461124300000247249719RearrangementMultiple myeloma
6174001142600000156500000Gain and amplificationMultiple myeloma
7174671142902432245422432GainMultiple myeloma
8206091153300000154800000GainAIM2Multiple myeloma
9206111153300000154800000GainEST1BMultiple myeloma
1020700115363086536308LossMultiple myeloma
11208481154800000157300000GainUFC1Multiple myeloma
12208491154800000158800000GainCAPONMultiple myeloma
13208821155000000156500000Gain and amplificationMultiple myeloma
14261521197500000205300000GainCHI3L1Multiple myeloma
15261531197500000205300000GainPTPN7Multiple myeloma
16261621197500000222100000GainGUK1Multiple myeloma
172949712326511323869113LossMultiple myeloma
18298291236600000249250621Gain and amplificationMultiple myeloma
193163612900000120700000GainCD53Multiple myeloma
203172913020000032400000Loss and deletionMultiple myeloma
2131749130500000184000000GainMultiple myeloma
223394315066945853683458LossMultiple myeloma
233394915070000059000000Loss and deletionMultiple myeloma
243518916090000069500000GainNFIAMultiple myeloma
253679118082142583677425LossMultiple myeloma
263696918417185496213854LossMultiple myeloma
273703518470000088100000GainMultiple myeloma
283704018470000094500000GainDISC1Multiple myeloma
29375191920000012700000Loss and deletionMultiple myeloma
3037525103076287130790767GainESTMultiple myeloma
313889810105800000114900000Loss and deletionMultiple myeloma
324040210127500000135534747Loss and deletionMultiple myeloma
3341379101730000022600000Gain and amplificati onMultiple myeloma
344857111100828925102320925LossANGPTL5Multiple myeloma
354857211100828925102320925LossBIRC2Multiple myeloma
364857311100828925102320925LossBIRC3Multiple myeloma
374857411100828925102320925LossKIAA1377Multiple myeloma
384857511100828925102320925LossMMP1Multiple myeloma
394857611100828925102320925LossMMP10Multiple myeloma
404857711100828925102320925LossMMP12Multiple myeloma
414857811100828925102320925LossMMP13Multiple myeloma
424857911100828925102320925LossMMP20Multiple myeloma
434858011100828925102320925LossMMP27Multiple myeloma
444858111100828925102320925LossMMP3Multiple myeloma
454858211100828925102320925LossMMP7Multiple myeloma
464858311100828925102320925LossMMP8Multiple myeloma
474858411100828925102320925LossPORIMINMultiple myeloma
484858511100828925102320925LossTRPC6Multiple myeloma
494858611100828925102320925LossYAP1Multiple myeloma
504966811110000000112800000GainPOU2AF1Multiple myeloma

Expression for genes affiliated with Multiple Myeloma

About this section
Search GEO for disease gene expression data for Multiple Myeloma.

Pathways for genes affiliated with Multiple Myeloma

About this section

Pathways related to Multiple Myeloma according to GeneCards Suite gene sharing:

(show all 25)
idSuper pathwaysScoreTop Affiliating Genes
110.3CCND1, IL6, IL6R
2
Show member pathways
10.3IL6, IL6R, IRF4
310.3DKK1, IL6, IL6R
410.3CCND1, IL6, MCL1
510.3CD19, IL6, IL6R
6
Show member pathways
10.3CCND1, CDK4, FGFR3
710.3CCND1, CCND3, IL6
8
Show member pathways
10.3IL6, IL6R, MCL1
910.3CCND1, CDK4, IL6
1010.3CCND1, CDK4, IL6
1110.3CD19, IL6, NCAM1
1210.3CCND1, CCND3, CDK4
1310.3CCND1, CCND3, CDK4
14
Show member pathways
10.3CCND1, CCND3, CDK4
1510.3CCND1, CCND3, CDK4
1610.2CD19, IL6, IRF4, NCAM1
1710.2CCND1, CCND3, CDK4, LIG4
18
Show member pathways
10.2CCND1, CCND3, CDK4, FGFR3
1910.2CCND1, CCND3, CDK4, DKK1
2010.2CCND1, CCND3, CDK4, IL6
2110.2CCND1, IL6, IL6R, IRF4, MCL1
22
Show member pathways
10.2CCND1, CCND3, IL6, IL6R, MCL1
23
Show member pathways
10.0BST2, CCND1, FGFR3, IL6, IL6R, IRF4
2410.0CCND1, CCND3, CD19, CDK4, FGFR3, IL6
25
Show member pathways
9.8BST2, C1orf35, CCND1, CD19, FGFR3, IL6

GO Terms for genes affiliated with Multiple Myeloma

About this section

Cellular components related to Multiple Myeloma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cell surfaceGO:000998610.5BST2, FGFR3, IL6R, MICA, NCAM1
2interleukin-6 receptor complexGO:000589610.4IL6, IL6R
3cyclin-dependent protein kinase holoenzyme complexGO:000030710.3CCND1, CCND3, CDK4

Biological processes related to Multiple Myeloma according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1hepatic immune responseGO:000238411.0IL6, IL6R
2interleukin-6-mediated signaling pathwayGO:007010211.0IL6, IL6R
3positive regulation of chemokine productionGO:003272210.9IL6, IL6R
4positive regulation of leukocyte chemotaxisGO:000269010.9IL6, IL6R
5positive regulation of tyrosine phosphorylation of STAT proteinGO:004253110.8FGFR3, IL6, IL6R
6positive regulation of tyrosine phosphorylation of Stat3 proteinGO:004251710.8FGFR3, IL6, IL6R
7regulation of insulin receptor signaling pathwayGO:004662610.8CCND3, CDK4
8positive regulation of cell proliferationGO:000828410.8CCND1, CDK4, FGFR3, IL6, IL6R
9response to cytokineGO:003409710.4IL6, IL6R, MCL1
10T-helper 17 cell lineage commitmentGO:007254010.4IL6, IRF4

Molecular functions related to Multiple Myeloma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1interleukin-6 receptor bindingGO:000513811.2IL6, IL6R
2cyclin-dependent protein serine/threonine kinase regulator activityGO:001653811.2CCND1, CDK4
3cyclin-dependent protein serine/threonine kinase activityGO:000469311.1CCND1, CCND3, CDK4
4protein bindingGO:00055159.4BST2, C1orf35, CCND1, CCND3, CD19, CDK4

Sources for Multiple Myeloma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet